Top Biotech Companies in Singapore (112)
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives,...
Align Technology's Top Stability & Growth Strengths
Strong Market Position & Advantage: Invisalign is broadly viewed as the clear leader in doctor‑directed clear aligners, reinforced by a large trained‑doctor base and an integrated digital workflow. Record Q4/FY 2025 volumes and revenue, alongside industry characterization as the market leader, support advantage durability.
Market Expansion: International regions (EMEA, Latin America, APAC) are cited as driving year‑over‑year volume growth, with contributions from teen/kids and adult segments and growing DSO/OSO channels. Continued gains outside North America align with guidance for additional growth into 2026.
Innovation-Driven Growth: An integrated platform spanning Invisalign, iTero scanners, and exocad software underpins a closed‑loop workflow that encourages adoption. Ongoing iTero Lumina upgrades and plans for directly 3D‑printed retainers/attachments in 2026 indicate a pipeline that can sustain future growth.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
Novotech is a global full‑service clinical research organization (CRO) and scientific advisory partner that provides clinical trial execution, regulatory, laboratory and consulting services to biotech and small- to mid‑sized pharmaceutical companies. Operating across the Asia‑Pacific region and beyond with multiple offices and strategic site partnerships, Novotech helps sponsors accelerate development and access diverse patient populations for global drug development.
KYAN Technologies, a pioneering leader in the field of precision medicine for oncology. Our company is dedicated to revolutionizing cancer care by leveraging cutting-edge technology and expertise. At KYAN, we have developed Optim.AI, a state-of-the-art Functional Precision Medicine test. This powerful tool empowers oncologists by providing them with critical insights to make informed clinical decisions for their patients. Our core...
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to...
Amgen's Top Stability & Growth Strengths
Strong Revenue Growth: 2025 results show total revenues up 10% to $36.8 billion and guidance for 2026 at $37.0–$38.4 billion signals continued top‑line expansion.
Diversified Revenue Streams: Company updates indicate a broad base with roughly 40 marketed products and 14 blockbusters in 2024, and in 2025 eighteen products reached record sales with notable growth from Repatha, TEZSPIRE, EVENITY, BLINCYTO, and rare‑disease brands.
Strong Market Position & Advantage: Evidence suggests Amgen is widely regarded as a leader among large‑cap biotechs with significant scale and an expanded rare‑disease footprint following the Horizon acquisition.
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to...
QIAGEN's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leadership in latent TB blood testing (QuantiFERON) and entrenched sample‑preparation technologies is reinforced by global guidelines and deep workflow stickiness. The company is also building share in digital PCR and competes credibly in syndromic panels despite strong incumbents.
Resilient & Sustainable Growth: Net sales grew in 2025 with guidance for further mid‑single‑digit growth in 2026, and earnings are guided to improve. Growth is increasingly driven by non‑COVID ‘pillars’ with recurring consumables and software that generally support steadier demand.
Future-Ready Strategy: Management pruned non‑core lines (e.g., NeuMoDx exit) and refocused investment on five growth pillars with multi‑year targets through 2028. Ongoing menu expansions, regulatory submissions, and targeted M&A (e.g., single‑cell and clinical genomics software) indicate continued positioning for scaled, profitable growth.
MMR Consulting Inc. and its dedicated team of experienced consultants are committed to delivering high quality, robust solutions for the Pharmaceutical and Biotechnology industries. Our expertise includes Engineering (Process, Automation, Facilities), Capital Project Management of large/complex projects and programs, Commissioning Qualification Validation, and GMP Compliance services.
NalaGenetics was built with the passion to make preventive, DNA-based precision healthcare accessible to as many people as possible. Specifically, catalyzed by the founders’ personal experiences of problematic medication side effects and knowledge of what genetic testing can offer, NalaGenetics aims to help people achieve better nutrition and prescription medication outcomes by analyzing their unique DNA. Today, NalaGenetics’ solutions are...
We are a digital-first, life sciences commercialization company. We help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. We bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions....
Indegene's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyst assessments place the company in leadership cohorts for life sciences commercial AI/analytics and digital services for commercial operations, indicating defensible positioning in its specialization. The company is also described as a best-fit provider for digital commercialization, omnichannel activation, content operations at scale, and AI-driven commercial analytics, reinforcing category leadership within that lane.
Strong Revenue Growth: Revenue shows clear acceleration into FY26, including a strong year-over-year increase in the latest reported quarter and a positive exit rate from prior quarters as deal wins converted. Full-year FY25 results also show year-over-year growth alongside continued profitability, supporting an upward growth trajectory.
Product Line Growth: Capability expansion is evidenced by recent acquisitions intended to deepen data-driven omnichannel, media offerings, and consulting/transformation coverage, broadening the commercialization toolkit. Ongoing scaling post-IPO is also framed as broadening capabilities beyond prior scope within its core focus areas.
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how...
GSK's Top Stability & Growth Strengths
Strong Market Position & Advantage: GSK is positioned as a top-tier global biopharmaceutical company by revenue while showing category leadership in vaccines and HIV, anchored by franchises such as Shingrix and ViiV’s portfolio. Its consistent top-10/12 standing and segment leadership in vaccines, respiratory, and HIV support a stable competitive footing.
Resilient & Sustainable Growth: Revenue and earnings momentum are supported by broad-based growth across Specialty Medicines and continued contributions from Vaccines, alongside reaffirmed multi-year sales ambitions. Guidance for continued turnover and profit expansion indicates an expectation of ongoing, steadier growth rather than a one-off spike.
Healthy Cash Flow: Operating cash generation is described as strong and is being used to fund R&D investment and shareholder returns such as dividends and buybacks. This cash profile supports resilience through investment cycles and potential volatility in specific product areas.
Vulcan Augmetics is building a distribution and data ecosystem for the $156BN biosignal sensor market. Using ML powered wireless EMG sensors with deep learning networks, our goal is to become the gateway between hardware and humanity, providing high fidelity biodata and feedback so that healthcare professionals can make better decisions for their patients, and everyday users can control their devices...
Umami Bioworks is a marine biotechnology company developing cultivated seafood and other marine-derived biosolutions. Its AI-driven ALKEMYST platform combines genomics, stem cell biology, machine learning, and automation to enable scalable, traceable, cruelty-free production. The company licenses modular systems to manufacturing partners and supports applications in seafood, cosmetics, and nutrition, aiming to reduce overfishing and ecosystem strain while improving sustainable food...
Our goal is to enable the analysis of anything, anywhere, by anyone. We have developed the world’s first and only nanopore DNA and RNA sequencing platform. It’s a new generation of sequencing technology — the only one to offer: scalability to portable or ultra-high throughput formats, real-time data delivery, and the ability to elucidate rich biological data. We are aiming to disrupt...
Oxford Nanopore Technologies's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.
Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.
Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.
Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and...
Catalent, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent analyses consistently place Catalent among the top global CDMOs, with meaningful presence in outsourced finished‑dose approvals and a broad end‑to‑end network. Its scale across oral, sterile, biologics, and cell & gene therapy supports late‑stage and commercial programs globally.
Investor Backing & Capital Strength: Novo Holdings’ completed acquisition provides deep‑capital sponsorship and strategic validation, with U.S./EU clearance reinforcing the platform’s importance. Related transactions around sterile sites highlight the strategic value of capabilities aligned to high‑demand medicines.
Future-Ready Strategy: Private ownership and a refreshed operating model aim to focus investment on biologics, cell & gene therapy, and clinical supply. GLP‑1–linked demand signals and capacity plans into the coming years indicate preparedness for sustained growth.
Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Learn...
We are a molecular life science company dedicated to advancing human health through innovation. By designing and building breakthrough molecular platforms that are both accessible and best-in-class, One BioMed is providing biomedical researchers and clinicians with unprecedented access to cutting-edge tools.
Livestock disease prevention and sustainable agri productivity. Singaporean synbio startup funded by EF Venture Capital.
Accelerating biological understanding and discovery is more than a mission for 10x Genomics. It’s a commitment. Fueled by equal parts scientific vision and determined passion, we are enabling fundamental research across the life sciences by delivering rapid innovation that allows our customers to resolve complex biology—across the fields of oncology, immunology, neuroscience, and more. As we deliver powerful new methods for...
10x Genomics's Top Stability & Growth Strengths
Strong Market Position & Advantage: 10x is widely regarded as the leader in single‑cell and a co‑leader in spatial biology, with Chromium, Visium and Xenium as reference platforms in many labs. Legal wins and injunctions in spatial further reinforce competitive positioning.
Product Line Growth: Ongoing chemistry and platform updates (GEM‑X, Visium HD, Xenium Protein/RNA multiomics) and launches like next‑gen Chromium Flex indicate continued expansion of content and capabilities. The planned acquisition of Scale Biosciences aims to broaden single‑cell workflows and support medium‑term growth.
Investor Backing & Capital Strength: The company maintains a sizable cash and securities balance alongside a large recurring consumables base. Management is prioritizing cash and costs while guiding quarter‑to‑quarter to navigate a softer funding environment.
Mouser Electronics is a worldwide leading authorized distributor of semiconductors and electronic components from over 1,100 manufacturer brands. We specialize in the rapid introduction of new products and technologies for design engineers and buyers. Our extensive product offering includes semiconductors, interconnects, passives, and electromechanical components. In 2007, Mouser became a part of the Warren Buffett Berkshire Hathaway family of companies. Today,...
Mouser Electronics's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry accounts position Mouser as a leader among authorized, high‑service distributors, with frequent “Distributor of the Year” awards and consistent inclusion on top distributor rankings. Its authorized model, NPI emphasis, and large automated Texas distribution center bolster competitive differentiation.
Product Line Growth: The line card expanded with 63 new manufacturers in 2025 and over 40,000 new parts, adding to a catalog of more than 6.8 million products from 1,200+ brands. This continued NPI‑led breadth supports design engineers and small‑to‑mid volume buyers.
Investor Backing & Capital Strength: As part of TTI within Berkshire Hathaway, the company benefits from financial stability and group scale. Parent disclosures highlight a 2025 rebound at TTI and ongoing investments in large‑scale warehouse automation and footprint expansion.
Axcynsis Therapeutics is at the forefront of developing cutting-edge Antibody Drug Conjugate (ADC) therapies. Our team's profound expertise, pioneering and proprietary ADC technology platform, enduring IP and know-how, substantial market opportunities, and strategic and effective execution position us as industry leaders in innovative cancer treatment solutions. At Axcynsis, our groundbreaking Matrix Optimization Platform is the cornerstone of our research and...



























